$1.11
3.74% day before yesterday
Nasdaq, Aug 22, 10:00 pm CET
ISIN
US36254L2097
Symbol
GTBP

GT Biopharma Inc Stock price

$1.11
-0.88 44.08% 1M
-0.92 45.32% 6M
-1.94 63.61% YTD
-1.05 48.61% 1Y
-78.69 98.61% 3Y
-90.69 98.79% 5Y
-652,161.39 100.00% 10Y
-15,682,498.89 100.00% 20Y
Nasdaq, Closing price Fri, Aug 22 2025
+0.04 3.74%
ISIN
US36254L2097
Symbol
GTBP
Industry

Key metrics

Basic
Market capitalization
$4.0m
Enterprise Value
$1.6m
Net debt
positive
Cash
$2.4m
Shares outstanding
2.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-39.5%
Return on Equity
788.1%
ROCE
1,347.5%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
- | $-14.4b
EBIT
$-13.2m | $-8.3m
Net Income
$-11.7m | $-5.1m
Free Cash Flow
$-10.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
-1.6% | 42.3%
Net Income
-21.1% | 61.6%
Free Cash Flow
-8.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-5.0
FCF per Share
$-4.3
Short interest
8.7%
Employees
1
Rev per Employee
$0.0
Show more

Is GT Biopharma Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

GT Biopharma Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a GT Biopharma Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a GT Biopharma Inc forecast:

Buy
86%
Hold
14%

Financial data from GT Biopharma Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 7.09 7.09
4% 4%
-
- Research and Development Expense 6.12 6.12
9% 9%
-
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -13 -13
2% 2%
-
Net Profit -12 -12
21% 21%
-

In millions USD.

Don't miss a Thing! We will send you all news about GT Biopharma Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

GT Biopharma Inc Stock News

Neutral
GlobeNewsWire
10 days ago
SAN FRANCISCO, CALIFORNIA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer (NK) cell engager TriKE® platform, today announced second quarter 2025 financial results for the period ended June 30, 2025.
Neutral
GlobeNewsWire
13 days ago
The first patient in Cohort 3, the fifth patient in the trial, has completed the first week of cycle 1 following the successful safety review of Cohort 2 with no safety or tolerability issues observed The company plans on releasing initial Phase 1 results later in 2025 following completion of additional dose cohorts
Neutral
GlobeNewsWire
2 months ago
SAN FRANCISCO, CALIFORNIA, June 13, 2025 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced the appointment of David C. Mun-Gavin to its Board of Directors.
More GT Biopharma Inc News

Company Profile

GT Biopharma, Inc. is a clinical stage biopharmaceutical company focused on the development and commercialization of immuno-oncology therapeutic products based proprietary TriKE NK cell engager platform. The TriKE platform is designed to harness and enhance the cancer killing abilities of a patient's immune system natural killer cells (NK cells). Its product GTB-3550 is initially developed for the treatment of AML and MDS, and other CD33+ hematologic cancers. GT Biopharma has worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology. The company was founded in 1965 and is headquartered in Beverly Hills, CA.

Head office United States
CEO Michael Breen
Employees 1
Founded 1965
Website www.gtbiopharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today